Celebrate International Clinical Trials' Day, ECRIN Urges
ECRIN is encouraging all clinical researchers to get involved in International Clinical Trials' Day.
The European Clinical Research Infrastructure Network (ECRIN) is encouraging all clinical researchers to get involved in International Clinical Trials' Day (ICTD), which takes place today (May 20).
ICTD is designed to coincide with the day that the Scottish physician James Lind started his famous trial in 1747. He was a pioneer of naval hygiene, and by conducting the first ever clinical trial, he developed the theory that citrus fruits cured scurvy. The objective is to make May 20 a focal point for international communication events, meetings, debates, and celebrations of clinical research.
This will be followed on May 21 by a project meeting being organized by ECRIN, ECRAN (European Communication on Research Awareness Needs), ICTD and CRP (Clinical Research Program) in Luxembourg. This meeting aims to promote a transnational communication on multinational clinical trials with the objective of facilitating better clinical research relevant to the needs of patients and highlight the important role of patients in clinical research.
For further details, go to http://www.ecranproject.eu/en/content/communicate-clinical-research-two-days-two-great-event.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
